FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1370-1372 March 29, 2007 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

"Death occurred about three months and a half after the onset of the acute disease and the lung was two thirds of the normal size, grayish in color, and hard as cartilage. Microscopically these areas showed advanced fibrotic changes and great thickening of the alveolar walls." Thus did Sir William Osler describe, in 1892, a case of idiopathic pulmonary fibrosis¹ — an unrelenting and progressive disease that afflicts more than 5 million patients worldwide. The number of patients who receive this diagnosis has doubled within the past decade, and yet there is no effective treatment. The overall prognosis is dismal, . . . [Full Text of this Article]

Source Information

From the Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and the University of Toronto — all in Toronto.

This article has been cited by other articles:

• Hardie, W. D., Davidson, C., Ikegami, M., Leikauf, G. D., Le Cras, T. D., Prestridge, A., Whitsett, J. A., Korfhagen, T. R. (2008). EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-{alpha}-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L1217-L1225 [Abstract] [Full Text]  
• Kim, H. P., Choi, A. M. K. (2008). Caveolin-1 stops profibrogenic signaling?. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L841-L842 [Full Text]